Franck E. Nicolini
About
Franck E. Nicolini is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Franck E. Nicolini has authored 91 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Hematology, 57 papers in Genetics and 25 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Franck E. Nicolini's work include Chronic Myeloid Leukemia Treatments (56 papers), Chronic Lymphocytic Leukemia Research (54 papers) and Acute Lymphoblastic Leukemia research (25 papers). Franck E. Nicolini is often cited by papers focused on Chronic Myeloid Leukemia Treatments (56 papers), Chronic Lymphocytic Leukemia Research (54 papers) and Acute Lymphoblastic Leukemia research (25 papers). Franck E. Nicolini collaborates with scholars based in France, United States and Italy. Franck E. Nicolini's co-authors include Connie J. Eaves, Tessa L. Holyoake, François‐Xavier Mahon, Gabriel Étienne, Sandrine Hayette, Mauricette Michallet, Xavier Thomas, Cédric Leroy, Delphine Réa and Paul W. Manley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Franck E. Nicolini
88 papers receiving 1.2k citations
Peers
Franck E. Nicolini
Cristina Arbona Spain
Timothy Devos Belgium
Elisabeth P. Nacheva United Kingdom
Fumitaka Nagamura Japan
Graciela Nogueras González United States
Alexandre Theocharides Switzerland
C. Dowding United Kingdom
Atsushi Wakita Japan
Christine Wolschke Germany
M. Freund Germany
Citations per year, relative to Franck E. Nicolini Franck E. Nicolini (= 1×)
peers
Cristina Arbona
Countries citing papers authored by Franck E. Nicolini
Since
Specialization
Citations
This map shows the geographic impact of Franck E. Nicolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck E. Nicolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck E. Nicolini more than expected).
Fields of papers citing papers by Franck E. Nicolini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Franck E. Nicolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck E. Nicolini. The network helps show where Franck E. Nicolini may publish in the future.
Co-authorship network of co-authors of Franck E. Nicolini
This figure shows the co-authorship network connecting the top 25 collaborators of Franck E. Nicolini. A scholar is included among the top collaborators of Franck E. Nicolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck E. Nicolini. Franck E. Nicolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jabbour, Elias, Jane F. Apperley, Jörge E. Cortes, et al.. (2024). Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 38(3). 475–481.
2.
Dulucq, Stéphanie, Françoise Rigal‐Huguet, Franck E. Nicolini, et al.. (2023). Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study. British Journal of Haematology. 201(6). 1116–1124.
3.
Bondeelle, Louise, Julien Gras, David Michonneau, et al.. (2019). Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 55(5). 982–986.
4.
Heiblig, Maël, Mohamed Elhamri, Marie Balsat, et al.. (2016). Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience. Leukemia & lymphoma. 58(1). 110–117.
5.
Nicolini, Franck E., Grzegorz Basak, Dong‐Wook Kim, et al.. (2015). The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation. Blood. 126(23). 480–480.
6.
Heiblig, Maël, Mohamed Elhamri, Franck E. Nicolini, et al.. (2015). Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. Clinical Lymphoma Myeloma & Leukemia. 15. S7–S13.
7.
Étienne, Gabriel, Delphine Réa, Joëlle Guilhot, et al.. (2015). Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients. Blood. 126(23). 345–345.
8.
Dulphy, Nicolas, Guylaine Henry, Joëlle Guilhot, et al.. (2013). Low Natural Killer (NK) Cell Counts and Functionality Are Associated With Molecular Relapse After Imatinib Discontinuation In Patients (pts) With Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) With Undetectable BCR-ABL Transcripts For At Least 2 Years: Preliminary Results From Immunostim, On Behalf Of STIM Investigators. Blood. 122(21). 856–856.
9.
Étienne, Gabriel, Stéphanie Dulucq, Franck E. Nicolini, et al.. (2013). Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 99(3). 458–464.
10.
Thomas, Xavier, Youcef Chelghoum, Giovanna Cannas, et al.. (2011). Leukocytosis and Circulating Blasts in Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Are They Valuable Factors for Therapeutic Decision-Making?. Clinical Lymphoma Myeloma & Leukemia. 11(4). 342–349.
11.
Michallet, Mauricette, Thomas Bénet, Mohamad Sobh, et al.. (2011). Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. European Journal of Clinical Microbiology & Infectious Diseases. 31(6). 991–997.
12.
Leprêtre, Frédéric, Sélim Corm, Franck E. Nicolini, et al.. (2010). Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leukemia Research. 35(4). 448–458.
13.
Étienne, Gabriel, B. Milpied, Delphine Réa, et al.. (2010). Recommandations du groupe Fi-LMC pour la gestion des effets indésirables du traitement par nilotinib (Tasigna®) au cours de la leucémie myéloïde chronique. Bulletin du Cancer. 97(8). 997–1009.
14.
Mahon, François‐Xavier, Sandrine Hayette, Valérie Lagarde, et al.. (2008). Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression. Cancer Research. 68(23). 9809–9816.
15.
Cheikh, Jean El, Mauricette Michallet, A Nagler, et al.. (2008). High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 93(3). 455–458.
16.
Mohty, Mohamad, Franck E. Nicolini, Frédéric Garban, et al.. (2008). Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. Blood. 112(11). 2165–2165.
17.
Michallet, Anne‐Sophie, Sabine Fürst, Valérie Dubois, et al.. (2005). Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced‐intensity conditioning regimens. British Journal of Haematology. 128(5). 676–689.
18.
Michallet, Mauricette, Quoc‐Hung Le, Anne‐Sophie Michallet, et al.. (2004). Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.. Blood. 104(11). 1821–1821.
19.
Nicolini, Franck E., et al.. (2004). Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion. Experimental Hematology. 32(11). 1033–1039.
20.
Szilvassy, Stephen J., Franck E. Nicolini, Connie J. Eaves, & Cindy Miller. (2003). Quantitation of Murine and Human Hematopoietic Stem Cells by Limiting-Dilution Analysis in Competitively Repopulated Hosts. Humana Press eBooks. 63. 167–187.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cristina Arbona Breakdown of academic impact, for papers by Timothy Devos Breakdown of academic impact, for papers by Elisabeth P. Nacheva Breakdown of academic impact, for papers by Fumitaka Nagamura Breakdown of academic impact, for papers by Graciela Nogueras González Breakdown of academic impact, for papers by Alexandre Theocharides Breakdown of academic impact, for papers by C. Dowding Breakdown of academic impact, for papers by Atsushi Wakita Breakdown of academic impact, for papers by Christine Wolschke Breakdown of academic impact, for papers by M. Freund